T-cell growth factors and the treatment of patients with cancer (Q36731948)

15 August 2017

1 reference

title

T-cell growth factors and the treatment of patients with cancer (English)

1 reference

15 August 2017

1 reference

https://api.crossref.org/works/10.1016/0090-1229(92)90040-U

10 November 2022

1 reference

M. T. Lotze

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1728987

10 November 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1728987

10 November 2022

publication date

1 January 1992

1 reference

full work available at URL

15 August 2017

https://api.elsevier.com/content/article/PII:009012299290040U?httpAccept=text/xml

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1016/0090-1229(92)90040-U

https://api.elsevier.com/content/article/PII:009012299290040U?httpAccept=text/plain

10 November 2022

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1016/0090-1229(92)90040-U

Clinical Immunology and Immunopathology

10 November 2022

published in

1 reference

15 August 2017

1 reference

15 August 2017

issue

1 Pt 2

1 reference

15 August 2017

page(s)

S47-54

1 reference

The immunologic treatment of cancer

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/0090-1229(92)90040-U

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

10 November 2022

1 reference

https://api.crossref.org/works/10.1016/0090-1229(92)90040-U

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

10 November 2022

1 reference

https://api.crossref.org/works/10.1016/0090-1229(92)90040-U

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

10 November 2022

1 reference

https://api.crossref.org/works/10.1016/0090-1229(92)90040-U

Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction

10 November 2022

1 reference

https://api.crossref.org/works/10.1016/0090-1229(92)90040-U

Stimulation of B-cell progenitors by cloned murine interleukin-7

10 November 2022

1 reference

https://api.crossref.org/works/10.1016/0090-1229(92)90040-U

Interleukin 7: effects on early events in lymphopoiesis

10 November 2022

1 reference

https://api.crossref.org/works/10.1016/0090-1229(92)90040-U

Interleukin 7 (murine pre-B cell growth factor/lymphopoietin 1) stimulates thymocyte growth: regulation by transforming growth factor beta

10 November 2022

1 reference

https://api.crossref.org/works/10.1016/0090-1229(92)90040-U

Effect of IL-7 on the growth of fetal thymocytes in culture

10 November 2022

1 reference

https://api.crossref.org/works/10.1016/0090-1229(92)90040-U

IL-7 induces human lymphokine-activated killer cell activity and is regulated by IL-4

10 November 2022

1 reference

https://api.crossref.org/works/10.1016/0090-1229(92)90040-U

IL-10, a novel growth cofactor for mature and immature T cells

10 November 2022

1 reference

https://api.crossref.org/works/10.1016/0090-1229(92)90040-U

Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI.

10 November 2022

1 reference

https://api.crossref.org/works/10.1016/0090-1229(92)90040-U

Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10

10 November 2022

1 reference

https://api.crossref.org/works/10.1016/0090-1229(92)90040-U

Identification of a novel thymocyte growth-promoting factor derived from B cell lymphomas.

10 November 2022

1 reference

https://api.crossref.org/works/10.1016/0090-1229(92)90040-U

Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells

10 November 2022

1 reference

https://api.crossref.org/works/10.1016/0090-1229(92)90040-U

Immunologic tolerance: collaboration between antigen and lymphokines

10 November 2022

1 reference

https://api.crossref.org/works/10.1016/0090-1229(92)90040-U

T cell tolerance by clonal elimination in the thymus

10 November 2022

1 reference

https://api.crossref.org/works/10.1016/0090-1229(92)90040-U

Peripheral tolerance to alloantigen results from altered regulation of the interleukin 2 pathway

10 November 2022

1 reference

https://api.crossref.org/works/10.1016/0090-1229(92)90040-U

A cell culture model for T lymphocyte clonal anergy

10 November 2022

1 reference

https://api.crossref.org/works/10.1016/0090-1229(92)90040-U

The effect of adrenalectomy and dexamethasone on interleukin-1 alpha induced responses in RIF-1 tumours

10 November 2022

1 reference

https://api.crossref.org/works/10.1016/0090-1229(92)90040-U

Corticosteroids inhibit the generation of lymphokine-activated killer activity in vitro

10 November 2022

1 reference

https://api.crossref.org/works/10.1016/0090-1229(92)90040-U

Regulation of murine lymphokine production in vivo. II. Dehydroepiandrosterone is a natural enhancer of interleukin 2 synthesis by helper T cells

10 November 2022

1 reference

https://api.crossref.org/works/10.1016/0090-1229(92)90040-U

Regulation of murine lymphokine production in vivo. III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function

10 November 2022

1 reference

https://api.crossref.org/works/10.1016/0090-1229(92)90040-U

10 November 2022

Identifiers

DOI

1 reference

15 August 2017

1 reference